RESUMEN

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

Asunto(s)

Antituberculosos/uso terapéutico , Diarilquinolinas/uso terapéutico , Uso Fuera de lo Indicado , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Adolescente , Antituberculosos/administración & dosificación , Antituberculosos/efectos adversos , Niño , Estudios de Cohortes , Diarilquinolinas/administración & dosificación , Diarilquinolinas/efectos adversos , Femenino , Humanos , Masculino